Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09

Reuters

05-15

<a href="https://laohu8.com/S/KOD">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09

Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535007098"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535007098\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535007098?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535007098","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&amp;D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-15 04:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&amp;D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL72T5xB:1","article_id":"2535007098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535007098","pubTimestamp":1747254272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc."},"translate_title":"Kodiak Sciences Inc.报告2025年第一季度净亏损增加5750万美元，每股收益下降至1.09美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    \n\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}